Low Molecular Weight Dextran Sulphate Safe in Phase 2 Study of ALS

Published Date: 28 Jul 2024

Over a 48-week period, patients treated with low molecular weight dextran sulfate compound had minimal changes in ALS Functional Rating Scale and ALS Assessment Questionnaire.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot